Consequences of the Cardiac Arrhythmia Suppression Trial: calamity or clarity?
Maloney
J D
JD
D000813:Anilides / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003257:Consumer Product Safety; D004311:Double-Blind Method; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects*; D006801:Humans; D007255:Information Services; D009316:National Institutes of Health (U.S.); D011897:Random Allocation; D014481:United States; D014486:United States Food and Drug Administration
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D005424:Flecainide; D016700:Encainide